menu search

IQV / IQVIA Holdings (IQV) CEO, Ari Bousbib on Q2 2022 Results - Earnings Call Transcript

IQVIA Holdings (IQV) CEO, Ari Bousbib on Q2 2022 Results - Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV ) Q2 2022 Earnings Conference Call July 21, 2022 9:00 AM ET Company Participants Ari Bousbib - Chairman, Chief Executive Officer Ron Bruehlman - Executive Vice President, Chief Financial Officer Mike Fedock - Senior Vice President, Financial Planning and Analysis Nick Childs - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Sandy Draper - Guggenheim Eric Coldwell - Baird Elizabeth Anderson - Evercore Derik de Bruin - Bank of America David Windley - Jefferies Jack Meehan - Nephron Research Adam - Stifel Tejas Savant - Morgan Stanley John Sourbeer - UBS Operator Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA second quarter 2022 earnings conference call. Read More
Posted: Jul 21 2022, 12:41
Author Name: Seeking Alpha
Views: 102281

IQV News  

IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates

By Zacks Investment Research
November 1, 2023

IQVIA Holdings (IQV) Q3 Earnings Surpass Estimates

IQVIA Holdings (IQV) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.46 per share. This compares to ea more_horizontal

IQVIA (IQV) and argenx Partner to Advance Autoimmune Care

By Zacks Investment Research
October 5, 2023

IQVIA (IQV) and argenx Partner to Advance Autoimmune Care

IQVIA (IQV) and argenx expand collaboration to advance rare autoimmune treatments through innovative pharmacovigilance. more_horizontal

Court strikes down federal rule that sharply increased prescription costs for many patients

By Market Watch
October 2, 2023

Court strikes down federal rule that sharply increased prescription costs for many patients

A federal court on Friday struck down a rule that sharply increased out-of-pocket prescription costs for many patients with complex conditions. more_horizontal

Here's Why Investors Should Retain IQVIA (IQV) Stock Now

By Zacks Investment Research
September 8, 2023

Here's Why Investors Should Retain IQVIA (IQV) Stock Now

An addressable market size and strong healthcare-specific global IT infrastructure boost IQVIA (IQV). more_horizontal

3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of

By InvestorPlace
August 30, 2023

3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of

This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so more_horizontal

IQVIA (IQV) Stock Improves 8% in Three Months: Here's How

By Zacks Investment Research
August 25, 2023

IQVIA (IQV) Stock Improves 8% in Three Months: Here's How

IQVIA (IQV) aims at market expansion through innovation and service improvements. more_horizontal

IQVIA Holdings' (IQV) Q2 Earnings Beat Estimates, Decline Y/Y

By Zacks Investment Research
August 1, 2023

IQVIA Holdings' (IQV) Q2 Earnings Beat Estimates, Decline Y/Y

IQVIA Holdings (IQV) second-quarter 2023 revenues improve year over year. more_horizontal

IQVIA (IQV) Reports Q2 Earnings: What Key Metrics Have to Say

By Zacks Investment Research
August 1, 2023

IQVIA (IQV) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering more_horizontal


Search within

Pages Search Results: